$173.9 M

CRVS Mkt cap, 12-Dec-2018
Corvus Pharmaceuticals Net income (Q2, 2018)-25.9 M
Corvus Pharmaceuticals EBIT (Q2, 2018)-26.9 M
Corvus Pharmaceuticals Cash, 30-Jun-201828.1 M

Corvus Pharmaceuticals Income Statement

Annual

USDFY, 2016FY, 2017

R&D expense

29.4m46.3m

General and administrative expense

7.6m10.2m

Operating expense total

37.0m56.5m

EBIT

(37.0m)(56.5m)

Net Income

(36.4m)(55.7m)

Quarterly

USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018Q2, 2018

R&D expense

5.4m7.1m7.7m13.5m12.4m12.1m21.8m

General and administrative expense

1.0m1.7m2.8m2.7m2.8m2.5m5.1m

Operating expense total

6.4m8.8m10.5m16.2m15.2m14.6m26.9m

EBIT

(6.4m)(8.8m)(10.5m)(16.2m)(15.2m)(14.6m)(26.9m)

Interest income

79.0k180.0k181.0k193.0k343.0k

Net Income

(6.3m)(8.6m)(10.3m)(16.0m)(15.0m)(14.3m)(25.9m)

Corvus Pharmaceuticals Balance Sheet

Annual

USDFY, 2016FY, 2017

Cash

5.1m45.1m

Current Assets

136.0m91.2m

PP&E

3.2m2.7m

Total Assets

140.2m94.8m

Accounts Payable

1.9m3.5m

Current Liabilities

5.9m9.0m

Total Liabilities

7.3m9.9m

Additional Paid-in Capital

200.7m208.4m

Retained Earnings

(67.9m)(123.5m)

Total Equity

132.8m84.8m

Financial Leverage

1.1 x1.1 x

Quarterly

USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018Q2, 2018

Cash

4.1m4.3m5.6m10.5m34.1m102.6m28.1m

Current Assets

154.1m153.5m146.0m123.1m111.6m145.2m134.4m

PP&E

2.6m2.8m2.9m3.1m3.0m2.5m2.3m

Total Assets

157.2m156.9m149.8m127.1m115.5m148.7m137.9m

Accounts Payable

1.6m1.3m2.4m2.4m4.1m3.5m2.3m

Current Liabilities

3.4m3.6m5.6m7.6m9.5m10.6m9.8m

Total Liabilities

4.7m5.0m6.9m8.9m10.7m11.5m10.5m

Additional Paid-in Capital

190.4m198.4m199.7m202.2m203.7m275.1m276.9m

Retained Earnings

(37.8m)(46.5m)(56.8m)(83.9m)(98.9m)(137.8m)(149.5m)

Total Equity

152.6m152.0m142.9m118.2m104.8m137.2m127.4m

Financial Leverage

1 x1 x1 x1.1 x1.1 x1.1 x1.1 x

Corvus Pharmaceuticals Cash Flow

Annual

USDFY, 2016FY, 2017

Net Income

(161.0k)(55.7m)

Depreciation and Amortization

842.0k

Accounts Payable

1.9m1.6m

Cash From Operating Activities

(46.2m)

Purchases of PP&E

(266.0k)

Cash From Investing Activities

84.8m

Cash From Financing Activities

1.4m

Quarterly

USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018Q2, 2018

Net Income

(6.3m)(15.0m)(10.3m)(16.0m)(31.0m)(14.3m)(25.9m)

Depreciation and Amortization

106.0k250.0k412.0k219.0k439.0k

Accounts Payable

(193.0k)129.0k2.4m2.4m2.3m45.0k(1.2m)

Cash From Operating Activities

(5.6m)(11.8m)(24.5m)(11.0m)(21.9m)

Purchases of PP&E

(614.0k)(1.5m)(232.0k)(6.0k)(60.0k)

Cash From Investing Activities

(58.7m)(59.4m)53.5m3.6m(60.0m)

Cash From Financing Activities

64.3m71.4m8.0k64.9m64.9m

Corvus Pharmaceuticals Ratios

USDY, 2018

Financial Leverage

1.1 x
Report incorrect company information

Corvus Pharmaceuticals Operating Metrics

FY, 2016

Patent Applications

11

Patents Licensed

18
Report incorrect company information

Corvus Pharmaceuticals Employee Rating

2.66 votes
Culture & Values
2.0
Work/Life Balance
2.7
Senior Management
2.0
Salary & Benefits
2.3
Career Opportunities
2.3
Source